Shares of Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) were down 1.8% on Wednesday . The company traded as low as $6.22 and last traded at $6.43, with a volume of 64,210 shares traded. The stock had previously closed at $6.55.

A number of analysts recently weighed in on FOMX shares. Zacks Investment Research upgraded shares of Foamix Pharmaceuticals from a “hold” rating to a “buy” rating and set a $6.75 price target for the company in a research note on Tuesday, March 8th. Guggenheim restated a “buy” rating and set a $10.00 price objective on shares of Foamix Pharmaceuticals in a research report on Tuesday, May 10th.

The stock has a 50 day moving average of $6.58 and a 200-day moving average of $6.63. The stock’s market cap is $199.27 million.

Foamix Pharmaceuticals (NASDAQ:FOMX) last posted its quarterly earnings data on Tuesday, May 10th. The specialty pharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.23) by $0.08. Equities analysts predict that Foamix Pharmaceuticals Ltd. will post ($0.89) earnings per share for the current fiscal year.

A hedge fund recently raised its stake in Foamix Pharmaceuticals stock. J. Goldman & Co LP boosted its stake in shares of Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) by 22.2% during the fourth quarter, Holdings Channel reports. The fund owned 580,000 shares of the specialty pharmaceutical company’s stock after buying an additional 105,190 shares during the period. J. Goldman & Co LP owned 1.90% of Foamix Pharmaceuticals worth $4,704,000 at the end of the most recent quarter.

Foamix Pharmaceuticals Ltd. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea, impetigo and other skin conditions. The Company operates in the segment of development and commercialization of foam-based formulations.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.